Validity, reliability, and sensitivity to change of the Thai version of the Migraine-Specific Quality of Life Questionnaire version 2.1

[1]Headache Classification Committee of the International Headache Society (IHS). The International classification of headache disorders, 3rd edition (beta version). Cephalalgia. 2013; 33:629–808.Headache Classification Committee of the International Headache Society (IHS)The International classification of headache disorders3rd(beta version)Cephalalgia20133362980810.1177/033310241348565823771276Search in Google Scholar

[2]Dahlöf CG. Measuring disability and quality of life in migraine. Drugs Today (Barc). 2003; 39 Suppl D:17–23.DahlöfCG.Measuring disability and quality of life in migraineDrugs Today (Barc)200339D172310.1046/j.1468-2982.2003.00580.xSearch in Google Scholar

[3]Freitag FG. The cycle of migraine: patients’ quality of life during and between migraine attacks. Clin Ther. 2007; 29:939–49.1769791310.1016/j.clinthera.2007.05.008FreitagFG.The cycle of migraine: patients’ quality of life during and between migraine attacksClin Ther.2007299394917697913Search in Google Scholar

[4]Clouse JC, Osterhaus JT. Healthcare resource use and costs associated with migraine in a managed healthcare setting. Ann Pharmacother. 1994; 28:659–64.10.1177/106002809402800518ClouseJCOsterhausJT.Healthcare resource use and costs associated with migraine in a managed healthcare settingAnn Pharmacother.199428659648069007Open DOISearch in Google Scholar

[5]Cavallini A, Micieli G, Bussone G, Rossi F, Nappi G. Headache and quality of life. Headache. 1995; 35:29–35.10.1111/j.1526-4610.1995.hed3501030.x7868331CavalliniAMicieliGBussoneGRossiFNappiG.Headache and quality of lifeHeadache.19953529357868331Open DOISearch in Google Scholar

[6]Wagner TH, Patrick DL, Galer BS, Berzon RA. A new instrument to assess the long-term quality of life effects from migraine: development and psychometric testing of the MSQOL. Headache. 1996; 36:484–92.10.1046/j.1526-4610.1996.3608484.x8824004WagnerTHPatrickDLGalerBSBerzonRA.A new instrument to assess the long-term quality of life effects from migraine: development and psychometric testing of the MSQOLHeadache.199636484928824004Open DOISearch in Google Scholar

[7]Jhingran P, Osterhaus JT, Miller DW, Lee JT, Kirchdoerfer L. Development and validation of the Migraine-Specific Quality of Life Questionnaire. Headache. 1998; 38:295–302.10.1046/j.1526-4610.1998.3804295.x9595870JhingranPOsterhausJTMillerDWLeeJTKirchdoerferL.Development and validation of the Migraine-Specific Quality of Life QuestionnaireHeadache.1998382953029595870Open DOISearch in Google Scholar

[8]Kosinski M, Bayliss MS, Bjorner JB, Ware JE Jr, Garber WH, Batenhorst A, et al. A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res. 2003; 12:963–74.10.1023/A:102611933119314651415KosinskiMBaylissMSBjornerJBWareJE JrGarberWHBatenhorstAA six-item short-form survey for measuring headache impact: the HIT-6Qual Life Res.20031296374Open DOISearch in Google Scholar

[9]Manhalter N, Bozsik G, Palásti A, Csépány E, Ertsey C. The validation of a new comprehensive headache-specific quality of life questionnaire. Cephalalgia. 2012; 32:668–82.10.1177/033310241244770222637722ManhalterNBozsikGPalástiACsépányEErtseyC.The validation of a new comprehensive headache-specific quality of life questionnaireCephalalgia.2012326688222637722Open DOISearch in Google Scholar

[10]Langeveld JH, Koot HM, Passchier J. Headache intensity and quality of life in adolescents. How are changes in headache intensity in adolescents related to changes in experienced quality of life? Headache. 1997; 37:37–42.LangeveldJHKootHMPasschierJ.Headache intensity and quality of life in adolescentsHow are changes in headache intensity in adolescents related to changes in experienced quality of life? Headache.199737374210.1046/j.1526-4610.1997.3701037.xSearch in Google Scholar

[11]Hartmaier SL, Santanello NC, Epstein RS, Silberstein SD. Development of a brief 24-hour Migraine-Specific Quality of Life Questionnaire. Headache. 1995; 35:320–9.763571710.1111/j.1526-4610.1995.hed3506320.xHartmaierSLSantanelloNCEpsteinRSSilbersteinSD.Development of a brief 24-hour Migraine-Specific Quality of Life QuestionnaireHeadache.19953532097635717Search in Google Scholar

[12]Jhingran P, Davis SM, LaVange LM, Miller DW, Helms RW. MSQ: migraine-specific quality-of-life questionnaire. Further investigation of the factor structure. Pharmacoeconomics. 1998; 13:707–17.10.2165/00019053-199813060-0000710179706JhingranPDavisSMLaVangeLMMillerDWHelmsRW.MSQ: migraine-specific quality-of-life questionnaire. Further investigation of the factor structurePharmacoeconomics.1998137071710179706Open DOISearch in Google Scholar

[13]Martin BC, Pathak DS, Sharfman MI, Adelman JU, Taylor F, Kwong WJ, et al. Validity and reliability of the Migraine-Specific Quality of Life Questionnaire (MSQ Version 2.1). Headache. 2000; 40:204–15.10.1046/j.1526-4610.2000.00030.x10759923MartinBCPathakDSSharfmanMIAdelmanJUTaylorFKwongWJValidity and reliability of the Migraine-Specific Quality of Life Questionnaire (MSQ Version 2.1)Headache.2000402041510759923Open DOISearch in Google Scholar

[14]Pathak D, Martin B, Kwong J, Batenhorst A. Evaluation of the Migraine-Specific Quality of Life Questionnaire (MSQ version 2.0) using confirmatory factor analysis. Qual Life Res. 1998; 7:647.PathakDMartinBKwongJBatenhorstA.Evaluation of the Migraine-Specific Quality of Life Questionnaire (MSQ version 2.0) using confirmatory factor analysisQual Life Res.19987647Search in Google Scholar

[15]Bagley CL, Rendas-Baum R, Maglinte GA, Yang M, Varon SF, Lee J, et al. Validating Migraine-Specific Quality of Life Questionnaire v2.1 in episodic and chronic migraine. Headache. 2012; 52:409–21.10.1111/j.1526-4610.2011.01997.x21929662BagleyCLRendas-BaumRMaglinteGAYangMVaronSFLeeJValidating Migraine-Specific Quality of Life Questionnaire v2.1 in episodic and chronic migraineHeadache.2012524092121929662Open DOISearch in Google Scholar

[16]Cole JC, Lin P, Rupnow MF. Validation of the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ v. 2.1) for patients undergoing prophylactic migraine treatment. Qual Life Res. 2007; 16:1231–7.10.1007/s11136-007-9217-117468941ColeJCLinPRupnowMF.Validation of the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ v. 2.1) for patients undergoing prophylactic migraine treatmentQual Life Res.2007161231717468941Open DOISearch in Google Scholar

[17]Dodick DW, Silberstein S, Saper J, Freitag FG, Cady RK, Rapoport AM, et al. The impact of topiramate on health-related quality of life indicators in chronic migraine. Headache. 2007; 47:1398–408.10.1111/j.1526-4610.2007.00950.x18052949DodickDWSilbersteinSSaperJFreitagFGCadyRKRapoportAMThe impact of topiramate on health-related quality of life indicators in chronic migraineHeadache.200747139840818052949Open DOISearch in Google Scholar

[18]Silberstein SD, Lipton R, Dodick D, Freitag F, Mathew N, Brandes J, et al. Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures. Headache. 2009; 49:1153–62.10.1111/j.1526-4610.2009.01508.xSilbersteinSDLiptonRDodickDFreitagFMathewNBrandesJTopiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measuresHeadache.20094911536219719543Open DOISearch in Google Scholar

[19]Yang M, Rendas-Baum R, Varon SF, Kosinski M. Validation of the Headache Impact Test (HIT-6™) across episodic and chronic migraine. Cephalalgia. 2011; 31:357–67.2081984210.1177/0333102410379890YangMRendas-BaumRVaronSFKosinskiM.Validation of the Headache Impact Test (HIT-6™) across episodic and chronic migraineCephalalgia.20113135767305742320819842Search in Google Scholar

[20]Rendas-Baum R, Yang M, Varon SF, Bloudek LM, DeGryse RE, Kosinski M. Validation of the Headache Impact Test (HIT-6) in patients with chronic migraine. Health Qual Life Outcomes. 2014; 12:117.10.1186/s12955-014-0117-025080874Rendas-BaumRYangMVaronSFBloudekLMDeGryseREKosinskiM.Validation of the Headache Impact Test (HIT-6) in patients with chronic migraineHealth Qual Life Outcomes.201412117424381925080874Open DOISearch in Google Scholar

[21]Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ, et al. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2007; 27:814–23.10.1111/j.1468-2982.2007.01326.xDienerHCBussoneGVan OeneJCLahayeMSchwalenSGoadsbyPJTopiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled studyCephalalgia.2007278142317441971Open DOISearch in Google Scholar

[22]Cady R, Schreiber C. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues. Headache. 2008; 48:900–13.1804750110.1111/j.1526-4610.2007.00953.xCadyRSchreiberC.Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issuesHeadache.2008489001318047501Search in Google Scholar

[23]De Diego EV, Lanteri-Minet M. Recognition and management of migraine in primary care: influence of functional impact measured by the headache impact test (HIT). Cephalalgia. 2005; 25:184–90.10.1111/j.1468-2982.2004.00820.x15689193De DiegoEVLanteri-MinetM.Recognition and management of migraine in primary care: influence of functional impact measured by the headache impact test (HIT)Cephalalgia.2005251849015689193Open DOISearch in Google Scholar

[24]Nachit-Ouinekh F, Dartigues JF, Henry P, Becg JP, Chastan G, Lemaire N, et al. Use of the headache impact test (HIT-6) in general practice: relationship with quality of life and severity. Eur J Neurol. 2005; 12:189–93.1569380710.1111/j.1468-1331.2004.00934.xNachit-OuinekhFDartiguesJFHenryPBecgJPChastanGLemaireNUse of the headache impact test (HIT-6) in general practice: relationship with quality of life and severityEur J Neurol.2005121899315693807Search in Google Scholar

[25]Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache classification committee of the International Headache Society. Cephalalgia. 1988; 8 Suppl 7:1–96.3048700Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache classification committee of the International Headache SocietyCephalalgia.198887196Search in Google Scholar

[26]Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders, second edition. Cephalalgia. 2004; 24 Suppl 1:1–160.Headache Classification Subcommittee of the International Headache SocietyThe international classification of headache disorderssecondCephalalgia.20042411160Search in Google Scholar

[27]Siegel S, Castellan NJ Jr, editors. Nonparametric statistics for the behavioural sciences. 2nd ed. Boston MA: McGraw Hill; 1988, p. 235–44.SiegelSCastellanNJ JrNonparametric statistics for the behavioural sciences.2ndBoston MAMcGraw Hill198823544Search in Google Scholar

[28]Zandifar A, Masjedi SS, Haghdoost F, Asgari F, Manouchehri N, Banihashemi M, et al. The psychometric properties of the Persian Migraine-Specific Quality Of Life Questionnaire version 2.1 in episodic and chronic migraines. Sci World J. 2013; 2013:950245.ZandifarAMasjediSSHaghdoostFAsgariFManouchehriNBanihashemiMThe psychometric properties of the Persian Migraine-Specific Quality Of Life Questionnaire version 2.1 in episodic and chronic migrainesSci World J.2013201395024510.1155/2013/950245377143924068887Search in Google Scholar

[29]Raggi A, Giovannetti AM, Schiavolin S, Leonardi M, Bussone G, Grazzi L, et al. Validating the Migraine-Specific Quality of Life Questionnaire v2.1 (MSQ) in Italian inpatients with chronic migraine with a history of medication overuse. Qual Life Res. 2014; 23:1273–7.10.1007/s11136-013-0556-924129671RaggiAGiovannettiAMSchiavolinSLeonardiMBussoneGGrazziLValidating the Migraine-Specific Quality of Life Questionnaire v2.1 (MSQ) in Italian inpatients with chronic migraine with a history of medication overuseQual Life Res.2014231273724129671Open DOISearch in Google Scholar

[30]Smitherman TA, Burch R, Sheikh H, Loder E. The prevalence, impact, and treatment of migraine and severe headaches in the United States: a review of statistics from national surveillance studies. Headache. 2013; 53:427–36.2347001510.1111/head.12074SmithermanTABurchRSheikhHLoderE.The prevalence, impact, and treatment of migraine and severe headaches in the United States: a review of statistics from national surveillance studiesHeadache.2013534273623470015Search in Google Scholar

[31]Kim BK, Chung YK, Kim JM, Lee KS, Chu MK. Prevalence, clinical characteristics and disability of migraine and probable migraine: a nationwide population-based survey in Korea. Cephalalgia. 2013; 33:1106–16.10.1177/0333102413484990KimBKChungYKKimJMLeeKSChuMK.Prevalence, clinical characteristics and disability of migraine and probable migraine: a nationwide population-based survey in KoreaCephalalgia.20133311061623615490Open DOISearch in Google Scholar

[32]Phanthumchinda K, Sithi-Amorn C. Prevalence and clinical features of migraine: a community survey in Bangkok, Thailand. Headache. 1989; 29:594–7.10.1111/j.1526-4610.1989.hed2909594.xPhanthumchindaKSithi-AmornC.Prevalence and clinical features of migraine: a community survey in Bangkok, ThailandHeadache.19892959472584001Open DOISearch in Google Scholar

[33]Spearman’s correlation Page. [online]. 2016 [cited 2016 Jun 22]. Available from: http://www.statstutor.ac.uk/resources/uploaded/spearmans.pdfSpearman’s correlation Page[online]2016[cited 2016 Jun 22]. Available fromhttp://www.statstutor.ac.uk/resources/uploaded/spearmans.pdfSearch in Google Scholar

[34]George D, Mallery P, editors. SPSS for Windows step by step: a simple guide and reference (11.0 update). 4th ed. Boston: Allyn and Bacon; 2003.GeorgeDMalleryPSPSS for Windows step by step: a simple guide and reference (11.0 update)4thBostonAllyn and Bacon2003Search in Google Scholar

[35]Silberstein SD. Preventive migraine treatment. Continuum (Minneap Minn). 2015; 21:973–89.26252585SilbersteinSD.Preventive migraine treatmentContinuum (Minneap Minn).2015219738910.1212/CON.0000000000000199464049926252585Search in Google Scholar

[36]Silberstein SD. Topiramate in migraine prevention: a 2016 perspective. Headache. 2017; 57:165–78.10.1111/head.1299727902848SilbersteinSD.Topiramate in migraine prevention: a 2016 perspectiveHeadache.2017571657827902848Open DOISearch in Google Scholar